-
Support for your Collaboration on Proof-of-concept clinical trial on the use of the 5-HT1A/1B Partial Agonist Eltoprazine for Treatment of L-DOPA-induced Dyskinesias. - Linked to Bjorklund CIA 2009
… fewer and fewer dopamine terminals survive, another neuron system kicks in: the serotonin neurons. The serotonin … transmitter,” but in a non-physiological manner. Studies in multiple pre-clinical models of the disease have shown that …
-
Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease
… immuno-modulatory and neuroprotective effects in cell-based systems, pre-clinical models of disease and clinical trials in multiple sclerosis and psoriasis patients. The biological …
-
LRRK2 Variation in Parkinson's Disease
… have also been the driving force behind disease-model systems and the directed the therapeutic intervention … variant. We will also assess the possible role of multiple LRRK2 variants acting together to result in disease …
-
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in non-human primates
May 13, 2020
… Parkinson’s disease (PD). Much evidence, accumulated from multiple experimental models, has suggested that α-syn plays … supporting the true multifactorial nature of PD, as multiple causes can induce a similar outcome regarding …
-
Paul Davies, PhD
… more recently motor neuron disease. He is also involved in multiple technology development projects in the areas of … ongoing in the Unit. Dr. Davies’ team also works on multiple industry projects and technology development. …
-
Farren Basil Shaw Briggs, PhD
… in genetic epidemiology. Dr. Briggs is a former National Multiple Sclerosis Society postdoctoral fellow. His research has focused on multiple sclerosis (MS), another complex neurodegenerative …